Parkinsonism — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for parkinsonism. 157 active patents protecting 2 drugs from 2+ originators. First major cliff: 2029. Daily refresh.

2
Approved drugs
157
Active US patents
53/100
Avg vulnerability
—
Annual revenue covered

Originators in Parkinsonism

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Aton 151 patents Merz 6 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating parkinsonism. Each bar = one year. Y-axis scaled to peak year (64 patents).

32
28
1
29
4
32
1
33
64
34
3
39

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Sinemet Cr
CARBIDOPA
 Aton 151 53 — 2028-12-26
Inbrija
LEVODOPA
 Merz 6 53 — 2029-02-03

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
RE43711 Inbrija method of use 75 2029-02-03
12458615 Inbrija method of use 75 2033-10-21
8377474 Sinemet Cr method of use 58 2028-12-26
9089607 Sinemet Cr method of use 58 2028-12-26
9089607 Sinemet Cr method of use 58 2028-12-26
8377474 Sinemet Cr method of use 58 2028-12-26
9533046 Sinemet Cr method of use 58 2028-12-26
9533046 Sinemet Cr method of use 58 2028-12-26
8377474 Sinemet Cr method of use 58 2028-12-26
8377474 Sinemet Cr method of use 58 2028-12-26

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
12303605 Sinemet Cr formulation 38 2034-10-07
12178918 Sinemet Cr formulation 38 2034-10-07
11357733 Sinemet Cr formulation 38 2034-10-07
11622941 Sinemet Cr formulation 38 2034-10-07
11622941 Sinemet Cr formulation 38 2034-10-07
12064521 Sinemet Cr formulation 38 2034-10-07
12064521 Sinemet Cr formulation 38 2034-10-07
12064521 Sinemet Cr formulation 38 2034-10-07
12178918 Sinemet Cr formulation 38 2034-10-07
11622941 Sinemet Cr formulation 38 2034-10-07

Related